Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Letermovir - Merck & Co

Drug Profile

Letermovir - Merck & Co

Alternative Names: AIC-001; AIC-090027; AIC-246; BAY-73-6327; MK-8228; PREVYMIS; PREVYMIS™-BMT; PREVYMIS™-SOT

Latest Information Update: 25 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Dana-Farber Cancer Institute; Merck & Co
  • Class Acetates; Antivirals; Fluorobenzenes; Phenyl ethers; Piperazines; Quinazolines; Small molecules
  • Mechanism of Action Terminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cytomegalovirus infections

Most Recent Events

  • 30 Nov 2023 Merck Sharp & Dohme in collaboration with National Institute of Allergy and Infectious Diseases completes a phase II ELICIT trial in Cytomegalovirus infections (In adults, In the elderly) in USA (PO) (NCT04840199)
  • 17 Oct 2023 Committee for Medicinal Products for Human Use (CHMP) recommends approval for extending dosing for PREVYMIS from 100 days to 200 days following transplant in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT) who are at risk for late cytomegalovirus (CMV) infections in EU
  • 17 Oct 2023 Committee for Medicinal Products for Human Use (CHMP) recommends approval of letermovir for cytomegalovirus (CMV) infections in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]) in EU
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top